| metastatic-recurrent HNSCC (mHNSCC) | ||
| mHNSCC - L1 - all population | mHNSCC - L1 - PDL1 positive | |
| immune chekpoint inhibitors | ||
| anti-PD-(L)1 | ||
| pembrolizumab based treatment | ||
| pembrolizumab alone | KEYNOTE-048 ... | KEYNOTE-048 ... KEYNOTE-048 ... |
| pembrolizumab plus 5FU plus platin | KEYNOTE-048 ... | KEYNOTE-048 ... KEYNOTE-048 ... |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
